By Connor Hart
Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses. Shares surge 266%, to $6.06, in after-hours trading.
Richardson Electronics reported higher sales and a smaller loss in its fiscal second quarter. The maker of engineered solutions and green energy products said sales rose 12% to $49.5 million for the quarter ended Nov. 30. Two analysts polled by FactSet had been looking for $51.3 million. The company's loss narrowed to 5 cents a share from 13 cents a share last year, though two analysts surveyed by FactSet had expected a loss of 2 cents a share. Shares fall 6.4%, to $13.80, in postmarket trading.
Instacart parent Maplebear was selected for inclusion in the S&P MidCap 400 index. The addition will go into effect on Jan. 14, when medical-technology company Enovis will move to the S&P SmallCap 600 from the S&P MidCap 400. Enovis is replacing Arch Resources, which is being sold to CONSOL Energy. Maplebear shares rise 4.8%, to $44.99, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 07, 2025 18:36 ET (23:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。